SANOFI PASTEUR
š«š·France
- Country
- š«š·France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
Phase 1
Completed
- Conditions
- DiphtheriaPertussisWhooping CoughTetanus
- Interventions
- Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3Biological: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis VaccineBiological: Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine AdsorbedBiological: Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1363
- Registration Number
- NCT02587520
Study of FluzoneĀ® Quadrivalent, FluzoneĀ® Intradermal Quadrivalent, and FluzoneĀ® High-Dose, Influenza Vaccines in Adults
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No PreservativeBiological: Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulationBiological: Fluzone High-Dose vaccine, 2015-2016 formulation
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 208
- Registration Number
- NCT02563093
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
Completed
- Conditions
- PregnancyInfluenza
- Interventions
- Biological: Quadrivalent Intradermal Influenza Vaccine (QIV)
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 87
- Registration Number
- NCT02554409
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: High-dose quadrivalent influenza virus vaccineBiological: High-dose influenza virus vaccineBiological: High-dose trivalent inactivated influenza vaccine
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 792
- Registration Number
- NCT02553343
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016Biological: Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT02550197
Safety and Immunogenicity of the 2015-2016 Formulation of FluzoneĀ® Quadrivalent (Influenza Vaccine) Among Healthy Children
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluzoneĀ® Quadrivalent Influenza Vaccine, No Preservative
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT02539108
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEVĀ®) in Healthy Subjects
Phase 3
Completed
- Conditions
- Japanese Encephalitis
- Interventions
- Biological: Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEVĀ®)
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 250
- Registration Number
- NCT02492165
- Locations
- š»š³
Preventive Medicine Centre of Hoa Binh Province, Hoa Binh, Vietnam
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No PreservativeBiological: Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No PreservativeBiological: Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No PreservativeBiological: Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 400
- Registration Number
- NCT02451358
A Study of Two Doses of Oral Cholera Vaccine (Shancholā¢) in Subjects Aged 1 Year and Older in Dominican Republic
Phase 3
Completed
- Conditions
- Cholera
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 336
- Registration Number
- NCT02434822
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Phase 3
Completed
- Conditions
- PertussisHepatitis BTetanusDiphtheriaHaemophilus Influenzae Type bPoliomyelitis
- Interventions
- Biological: HexaximĀ®
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 354
- Registration Number
- NCT02428491
- Locations
- š»š³
Preventive Medicine Centre of Thai Binh Province, Thai Binh, Vietnam
Ā© Copyright 2025. All Rights Reserved by MedPath